Journal of diabetes and its complications最新文献

{"title":"The cardiovascular–kidney–metabolic staging in type 2 diabetes: the clock starts ticking early","authors":"Karolina Hoffmann ,&nbsp;Anna Paczkowska ,&nbsp;Viviana Maggio ,&nbsp;Manfredi Rizzo","doi":"10.1016/j.jdiacomp.2025.109177","DOIUrl":"10.1016/j.jdiacomp.2025.109177","url":null,"abstract":"<div><div>Nishizawa et al. demonstrate that cardiovascular–kidney–metabolic (CKM) staging is a strong predictor of all-cause mortality in type 2 diabetes, even before contemporary ardiorenal therapies were widely available. In their cohort, mortality rose sharply from stage 3 onward, underscoring that pathological risk begins well before overt cardiorenal failure. Because CKM staging relies on routine clinical data, it offers a pragmatic framework for early risk stratification, yet it is often applied too late. Integrating CKM assessment into electronic health systems and initiating cardiorenalprotective interventions in stages 1–2 could substantially improve outcomes. Future studies should validate CKM staging in modern therapy settings and evaluate stageguided interventions.</div></div>","PeriodicalId":15659,"journal":{"name":"Journal of diabetes and its complications","volume":"39 11","pages":"Article 109177"},"PeriodicalIF":3.1,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145109382","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A comparative analysis of cost-utility: Chiglitazar vs. sitagliptin in patients with type 2 diabetes in China","authors":"Zeyu Xie ,&nbsp;Zhuoru Liang ,&nbsp;Guimei Zheng ,&nbsp;Weiling Cao","doi":"10.1016/j.jdiacomp.2025.109174","DOIUrl":"10.1016/j.jdiacomp.2025.109174","url":null,"abstract":"<div><h3>Background</h3><div>As a structurally unique peroxisome proliferator-activated receptor pan-agonist, chiglitazar has showed dual therapeutic benefits for glycemic control and lipid management in type 2 diabetes mellitus (T2DM). Despite these clinical advantages, comprehensive pharmacoeconomic evaluations comparing chiglitazar with conventional therapies like sitagliptin remain unavailable for China's healthcare system.</div></div><div><h3>Objective</h3><div>This study aimed to conduct a comparative cost-utility analysis of chiglitazar versus sitagliptin for T2DM treatment in China, evaluating long-term clinical and economic outcomes from a healthcare system perspective.</div></div><div><h3>Methods</h3><div>Data on patient demographics and post-treatment effects were collected from a double-blind, phase 3, randomized controlled trial conducted in China. The United Kingdom Prospective Diabetes Study Outcomes Model 2.1 was employed to evaluate the long-term effectiveness and associated costs. Uncertainties were addressed using one-way and probabilistic sensitivity analyses. Additionally, the binary search method was utilized to estimate an optimal annual cost for sitagliptin in scenario analyses.</div></div><div><h3>Results</h3><div>After a 40-year simulation, the life expectancy results were comparable among treatments: 14.93 years for chiglitazar 32 mg, 14.94 years for chiglitazar 48 mg, and 14.93 years for sitagliptin 100 mg. The corresponding quality-adjusted life years (QALYs) reached 12.82, 12.83, and 12.81, respectively. Total accumulated costs over the simulation period were $44,241.09 (chiglitazar 32 mg), $45,044.25 (chiglitazar 48 mg), and $44,821.45 (sitagliptin 100 mg). Long-term economic evaluation revealed that chiglitazar 32 mg provided the optimal cost-effectiveness, whereas sitagliptin 100 mg was the least economically advantageous option. Both one-way and probabilistic sensitivity analyses confirmed the robustness of these findings. Scenario analysis showed that sitagliptin 100 mg only becomes cost-effective when its annual cost is reduced by at least 42.33 % compared to chiglitazar 32 mg.</div></div><div><h3>Conclusion</h3><div>Based on cost-utility analysis within the Chinese healthcare context, chiglitazar demonstrates significantly better long-term health outcomes and cost-effectiveness relative to sitagliptin for T2DM management.</div></div>","PeriodicalId":15659,"journal":{"name":"Journal of diabetes and its complications","volume":"39 11","pages":"Article 109174"},"PeriodicalIF":3.1,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145047102","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy of levocetirizine in reducing albuminuria and inflammatory biomarkers in patients with diabetic kidney disease: A randomized controlled trial","authors":"Maryam A. Rizk ,&nbsp;Sahar M. El-Haggar ,&nbsp;Osama M. Ibrahim ,&nbsp;Hossam Arafa Ghazi","doi":"10.1016/j.jdiacomp.2025.109175","DOIUrl":"10.1016/j.jdiacomp.2025.109175","url":null,"abstract":"<div><div>Globally, the prevalence of diabetes mellitus is rising. One of the main causes of end-stage renal disease (ESRD) and a risk factor for higher morbidity and death in diabetic patients is diabetic nephropathy (DN), sometimes referred to as diabetic kidney disease (DKD). DN, a microvascular consequence of diabetes, affects 20–40 % of diabetics globally. The study's objective was to assess if levocetirizine may have albuminuria lowering effect and anti-inflammatory effect in patients treated with angiotensin receptor blockers (ARBs) and sodium-glucose cotransporter 2 (SGLT2) inhibitors therapy by reducing albuminuria and improving DKD indicators.</div></div><div><h3>Patients and methods</h3><div>A controlled, parallel, trial was carried out on sixty DKD patients. Sixty patients were divided into two groups at random. Group 1 (control group) received an empagliflozin 10 mg once day in addition to 80 mg valsartan. Group 2 (levocetirizine group) received the same medications as the control group plus a 5 mg of levocetirizine once daily in the evening, titrated dose based on each patient's creatinine clearance (CrCl) for three months. Serum creatinine, serum urea, serum cystatin-C, HbA₁c, tumor necrosis factor alpha (TNF-α), estimated glomerular filtration rate (eGFR), and urinary albumin to creatinine ratio (UACR) were measured at baseline and compared to these data three months after drug administration.</div></div><div><h3>Results</h3><div>Levocetirizine decreased significantly UACR at the end of the three-months (<em>p</em> = 0.037) compared to the control group. There was no variation in eGFR between the two groups, eGFR was significantly lower than baseline (<em>p</em> &lt; 0.001) in both groups. Comparing the levocetirizine group to the control group, there is a substantial drop in TNF-α (<em>p</em> = 0.004), cystatin-C (<em>p</em> = 0.034), and HbA₁c (<em>p</em> = 0.007).</div></div><div><h3>Conclusion</h3><div>Levocetirizine reduces albuminuria, inflammatory, and renal indicators, which makes it a potentially has albuminuria lowering effect and anti-inflammatory drug which decreases disease progression.</div></div><div><h3>Trial registration identifier</h3><div><span><span>NCT05638880</span><svg><path></path></svg></span></div></div>","PeriodicalId":15659,"journal":{"name":"Journal of diabetes and its complications","volume":"39 11","pages":"Article 109175"},"PeriodicalIF":3.1,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145047103","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Can fibrate therapy redefine the management of diabetic retinopathy? A comprehensive systematic review and meta-analysis of efficacy and safety","authors":"Kai-Yang Chen ,&nbsp;Hoi-Chun Chan ,&nbsp;Chi-Ming Chan","doi":"10.1016/j.jdiacomp.2025.109178","DOIUrl":"10.1016/j.jdiacomp.2025.109178","url":null,"abstract":"&lt;div&gt;&lt;h3&gt;Background&lt;/h3&gt;&lt;div&gt;Diabetic retinopathy (DR) is a severe microvascular diabetes complication and a leading cause of preventable blindness. Fibrates, being lipid-lowering agents, have been found to have promise in modifying DR progression.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Objective&lt;/h3&gt;&lt;div&gt;To determine fibrates' effectiveness and safety profile in reducing the incidence, progression, and severity of diabetic retinopathy.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Methods&lt;/h3&gt;&lt;div&gt;Randomized controlled trials and observational cohort studies that compared fibrate therapy with no fibrate therapy in patients with diabetes were eligible for this systematic review and meta-analysis. The outcomes of interest included the incidence of DR, long-term progression, progression to Proliferative Diabetic Retinopathy (PDR), and adverse effects. Risk of bias was assessed using the RoB 2 and ROBINS-I tools, and results were synthesized narratively due to heterogeneity in the study populations, follow-up durations, and diagnostic methods.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Results&lt;/h3&gt;&lt;div&gt;Only 17 articles were eligible for inclusion in this study. Fibrates significantly reduced the incidence of diabetic retinopathy (OR 0.72 (95 % CI: 0.66–0.77), &lt;em&gt;p&lt;/em&gt; &lt; 0.001; I&lt;sup&gt;2&lt;/sup&gt; = 26.53 %) and slowed long-term progression (OR 0.67 (95 % CI: 0.57–0.79), p &lt; 0.001).; I&lt;sup&gt;2&lt;/sup&gt; = 26.39 %) compared to placebo. Combining fibrates with statin reduces DR progression by 17 % compared to fibrate alone HR 0.84 (95 % CI: 0.80–0.89), &lt;em&gt;p&lt;/em&gt; &lt; 0.001; I&lt;sup&gt;2&lt;/sup&gt; = 31.7 %. While progression to proliferative diabetic retinopathy showed a favorable trend (RR 0.71 (95 % CI: 0.15–3.32), &lt;em&gt;p&lt;/em&gt; = 0.67, the result was not statistically significant. Analysis of adverse events, including all-cause mortality (OR 0.86 (95 % CI: 0.62–1.19), &lt;em&gt;p&lt;/em&gt; = 0.36; I&lt;sup&gt;2&lt;/sup&gt; = 0 %), revealed no significant safety benefits in comparison between fibrates and placebo.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Conclusion&lt;/h3&gt;&lt;div&gt;Fibrates significantly reduce both the incidence and long-term progression of diabetic retinopathy. Safety analyses revealed no significant difference between placebo and fibrates in reducing serious adverse events or all-cause mortality.&lt;/div&gt;&lt;div&gt;&lt;strong&gt;What is known about this research topic?&lt;/strong&gt;&lt;ul&gt;&lt;li&gt;&lt;span&gt;•&lt;/span&gt;&lt;span&gt;&lt;div&gt;Diabetic retinopathy (DR) is a leading cause of preventable blindness, with limited systemic therapies beyond glycemic and blood pressure control.&lt;/div&gt;&lt;/span&gt;&lt;/li&gt;&lt;li&gt;&lt;span&gt;•&lt;/span&gt;&lt;span&gt;&lt;div&gt;Fibrates, primarily lipid-lowering agents, have shown potential benefits for microvascular complications, including DR, in trials like FIELD and ACCORD Eye.&lt;/div&gt;&lt;/span&gt;&lt;/li&gt;&lt;/ul&gt;&lt;/div&gt;&lt;div&gt;&lt;strong&gt;What this study adds and its future implications&lt;/strong&gt;&lt;ul&gt;&lt;li&gt;&lt;span&gt;•&lt;/span&gt;&lt;span&gt;&lt;div&gt;This meta-analysis confirms fibrates significantly reduce the incidence and long-term progression of DR, with fenofibrate showing the greatest benefit.&lt;/div&gt;&lt;/span&gt;&lt;/li&gt;&lt;li&gt;&lt;span&gt;•&lt;/span&gt;&lt;span&gt;&lt;div&gt;Alt","PeriodicalId":15659,"journal":{"name":"Journal of diabetes and its complications","volume":"39 11","pages":"Article 109178"},"PeriodicalIF":3.1,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145212843","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Response to the letter to the editor","authors":"Fernando Sebastian-Valles","doi":"10.1016/j.jdiacomp.2025.109160","DOIUrl":"10.1016/j.jdiacomp.2025.109160","url":null,"abstract":"","PeriodicalId":15659,"journal":{"name":"Journal of diabetes and its complications","volume":"39 11","pages":"Article 109160"},"PeriodicalIF":3.1,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145000702","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Semaglutide and the retina: Weighing evidence against concern","authors":"Emir Muzurović ,&nbsp;Ksenija Zečević ,&nbsp;Viviana Maggio ,&nbsp;Mohamed El Tanani ,&nbsp;Manfredi Rizzo","doi":"10.1016/j.jdiacomp.2025.109148","DOIUrl":"10.1016/j.jdiacomp.2025.109148","url":null,"abstract":"","PeriodicalId":15659,"journal":{"name":"Journal of diabetes and its complications","volume":"39 11","pages":"Article 109148"},"PeriodicalIF":3.1,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144794659","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Letter to “Impact of remnant cholesterol and triglycerides on diabetes foot and disease in type 1 diabetes: A propensity score-matched case-control study”","authors":"XiaoMei Wang ,&nbsp;SongQian Yang","doi":"10.1016/j.jdiacomp.2025.109156","DOIUrl":"10.1016/j.jdiacomp.2025.109156","url":null,"abstract":"","PeriodicalId":15659,"journal":{"name":"Journal of diabetes and its complications","volume":"39 11","pages":"Article 109156"},"PeriodicalIF":3.1,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145000696","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The prevalence of diabetic neuropathy in Greenland and its association with Inuit genetic ancestry – a cross-sectional study","authors":"Marie Mathilde Bjerg Christensen ,&nbsp;Christian Stevns Hansen ,&nbsp;Jesper Fleischer ,&nbsp;Ninna Senftleber ,&nbsp;Frederik Filip Stæger ,&nbsp;Torben Hansen ,&nbsp;Daniel R. Witte ,&nbsp;Marit Eika Jørgensen","doi":"10.1016/j.jdiacomp.2025.109179","DOIUrl":"10.1016/j.jdiacomp.2025.109179","url":null,"abstract":"<div><h3>Aims</h3><div>Data on diabetic neuropathies in Greenland remains limited. The aim was to estimate the prevalence of diabetic peripheral neuropathy (DPN) and cardiovascular autonomic neuropathy (CAN) among Greenlanders with diabetes and prediabetes and investigate whether Inuit ancestry contributes to higher susceptibility.</div></div><div><h3>Methods</h3><div>Individuals with diabetes and prediabetes from the Greenland Population Survey 2018 were examined for DPN (Vibration Perception Threshold (VPT) and light pressure) and CAN (Cardiovascular Reflex Tests and Heart Rate Variability). Inuit genetic admixture was included as a determinant in regression models adjusted for age, sex, genetics, diabetes status and residency.</div></div><div><h3>Results</h3><div>Among 447 participants (1/3 diabetes, median age 61, 57 % female) DPN prevalence was 28 % in diabetes and 25 % in prediabetes. CAN prevalence was 24 % and 15 %, respectively. A 20-percentage point change in Inuit ancestry was associated with a 4 % higher VPT (coefficient: 1.04, 95 % CI: 1.003–1.08) and 51 % higher odds of CAN (OR: 1.51, 95 % CI: 1.09–2.08).</div></div><div><h3>Conclusions</h3><div>DPN and CAN are common among Greenlanders with diabetes and prediabetes, highlighting the need for improved diagnostics and prevention. The association between Inuit genetic ancestry and neuropathy suggests a predisposition to neuropathy among Inuit, which may be explained by both genetic and lifestyle factors.</div></div>","PeriodicalId":15659,"journal":{"name":"Journal of diabetes and its complications","volume":"39 11","pages":"Article 109179"},"PeriodicalIF":3.1,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145244504","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Trends in mean serum insulin and hyperinsulinemia among US adults without diabetes 1999–2018","authors":"Tammie M. Johnson ,&nbsp;James R. Churilla","doi":"10.1016/j.jdiacomp.2025.109159","DOIUrl":"10.1016/j.jdiacomp.2025.109159","url":null,"abstract":"<div><h3>Purpose</h3><div>The purpose of this study is to examine trends for mean serum insulin concentration (pmol/L) and prevalence of hyperinsulinemia (≥4.358 pmol/L fasting insulin) in US adults without diabetes.</div></div><div><h3>Methods</h3><div>We used data from the 1999–2018 National Health and Nutrition Examination Survey (NHANES). Participants (<em>n</em> = 14,150) were ≥20 years of age, not pregnant, had no history of diabetes, had a fasting blood glucose measure of less than 126 mg/dL, and had valid responses to all study variables. Consecutive cycles of NHANES data from 1999 to 2018 (20 years) were aggregated into five four-year intervals.</div></div><div><h3>Results</h3><div>The Annual Percent Change (APC) for mean fasting insulin ranged from 5.64 (adjusted for body mass index) to 7.65 % when unadjusted (all <em>p</em>-values for trend &lt;0.0001). The APC for hyperinsulinemia prevalence ranged from 19.4 % (adjusted for waist circumference) to 22.3 % when unadjusted (all <em>p</em>-values for trend &lt;0.0001). The subanalyses by gender consistently revealed significant positive trends for both outcomes.</div></div><div><h3>Conclusions</h3><div>This study illustrates a significant positive trend for mean fasting insulin concentrations and hyperinsulinemia among US adults over 20 years. Monitoring serum insulin and hyperinsulinemia trends provides insights into the continuing rise in type 2 diabetes (T2D) and opportunities for T2D prevention.</div></div>","PeriodicalId":15659,"journal":{"name":"Journal of diabetes and its complications","volume":"39 11","pages":"Article 109159"},"PeriodicalIF":3.1,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144997677","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Burden and progression of arterial calcification in type 1 diabetes predicts future cardiovascular disease","authors":"Henrik Ø. Hjortkjær ,&nbsp;Peter Rossing ,&nbsp;Klaus F. Kofoed","doi":"10.1016/j.jdiacomp.2025.109152","DOIUrl":"10.1016/j.jdiacomp.2025.109152","url":null,"abstract":"<div><h3>Aims</h3><div>Even in the absence of kidney disease in persons with type 1 diabetes, there is an increased risk of cardiovascular (CV) disease through mechanisms not fully understood. This study aims to investigate whether evaluating arterial calcification can augment CV risk stratification in people with type 1 diabetes.</div></div><div><h3>Methods</h3><div>Persons with type 1 diabetes included in previous studies evaluating subclinical CV disease with CT scans of arterial beds in 75 persons without kidney disease were assessed for major adverse CV events (MACE) defined as CV-death, ischemic heart disease, heart failure, stroke, coronary interventions, and/or peripheral artery intervention. CT allowed for evaluation of coronary artery calcium score (CACS), progression of coronary artery calcium and generalised arterial calcification in multiple arterial beds. Cox regression was used for survival analyses.</div></div><div><h3>Results</h3><div>Seventy-three persons were available for endpoint evaluation and 16 (22 %) experienced a MACE after a median follow-up of 12.4 years (IQR 9.1–12.8). In unadjusted analyses, MACE was associated with baseline CACS &gt; 10 (<em>p</em> = 0.003), progression of coronary artery calcium (<em>p</em> = 0.03) and generalised arterial calcification (<em>p</em> = 0.006). After adjustment for diabetes duration, baseline CACS &gt; 10 remained associated with increased risk of MACE (<em>p</em> = 0.04).</div></div><div><h3>Conclusions</h3><div>This study shows that increased CACS entails increased risk of future MACE in persons with type 1 diabetes without kidney- or prior CV disease. This finding suggests that CACS evaluation may help differentiate CV risk management in persons with long-term type 1 diabetes without evidence of kidney disease and thus may be another step towards individualised medicine.</div></div>","PeriodicalId":15659,"journal":{"name":"Journal of diabetes and its complications","volume":"39 10","pages":"Article 109152"},"PeriodicalIF":3.1,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144913570","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}